Biogen and Capsigen recently entered into a collaboration to engineer novel adeno-associated virus (AAV) capsids to deliver gene therapies that address genetic causes of various central nervous system...
Eli Lilly and Company and MiNA Therapeutics recently entered into a global research collaboration that will leverage small activating RNA (saRNA) research technology for drug discovery.
MiNA...
TCR2 Therapeutics recently announced that it has signed a long-term, full-binding lease with Alexandra Real Estate Equities for an existing 85,000 square foot cell therapy manufacturing...
FDA recently approved Abecma, the first cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to or whose disease has returned after previous...
Pharmaceutical company bluebird bio recently announced that it suspended Phase 1/2 and Phase 3 studies of LentiGlobin gene therapy for sickle cell disease due to a suspected unexpected serious adverse...
Pfizer recently announced that the first participant has been dosed in the Phase 3 study to evaluate the safety of its investigational rare disease gene therapy candidate in boys with Duchenne muscular...
Kite, a Gilead Company, and Oxford BioTherapeutics recently entered into a collaboration to research and evaluate five novel cell therapies for hematologic and solid tumor indications.
Oxford...
Fujifilm Corporation will invest $40 million to establish a new processing facility to advance viral vector manufacturing and perform cutting-edge research in the field of advanced therapies in the...
Eli Lilly & Company recently announced that it will acquire Prevail Therapeutics in an $800 million pharmaceutical acquisition deal.
The acquisition agreement will establish a new modality for...
Thermo Fisher Scientific recently announced the construction of a new cGMP plasmid DNA manufacturing facility in California to expand the company’s efforts in gene and cell therapy development,...
Cerner recently announced that an investment in Elligo Health Research will increase access to clinical trials by offering clinical trial resourcesin the Cerner Learning Health...
Bayer recently announced the launch of a cell and gene therapy platform (C>) within its pharmaceutical division.
The platform will further consolidate its emerging leadership in the cell and...
Eli Lilly & Company and Precision BioSciences recently announced a collaboration to research and develop potential in vivo gene therapies for genetic disorders.
The collaboration and exclusive...
Thermo Fisher Scientific and the Biopharmaceutical Analysis Training Laboratory (BATL) at Northeastern University recently entered into an agreement to drive innovation across the...
Sanofi recently signed a definitive agreement to acquire biopharmaceutical company, Kiadis, in a $359 million pharma acquisition deal.
Under the agreement, Sanofi will offer $6.40 per share to develop...
Bayer recently announced a $4 billion pharma acquisition deal with Asklepios BioPharmaceutical (AskBio) to broaden its base in cell and gene therapy.
As part of the acquisition deal, Bayer...
CRISPR Therapeutics, recently announced positive top-line results from its ongoing Phase 1 clinical trial evaluating the safety and efficacy of its allogeneic CAR-T cell therapy that targets...
Pfizer and Sangamo Therapeutics recently announced that the first patient has been dosed in the Phase 3 study of an investigational gene therapy for hemophilia A patients.
The Phase 3 AFFINE study is...
Eli Lilly and Amgen recently announced a global manufacturing collaboration to increase the supply of Lilly’s potential COVID-19 antibody therapies.
If one or more of Lilly’s...
Bristol Myers Squibb and bluebird bio, Inc. recently announced that FDA accepted their request for a priority review for Idecabtagene vicleucel, a chimeric antigen receptor (CAR) T-cell therapy for the...
